The benefit of such approach is based on avoiding inherent complications related to major
abdominal incision. Laparoscopy is usually associated with less postoperative pain, hospital stay and an earlier capacity to return to work. Mortality and mrbidity of CRS and HIPEC The morbidity and mortality after CRS and HIPEC range from 12% to 41% and from 0% to 8%, respectively (12-24) (Table 4, Figure 3). Morbidity can be divided into surgery-related and Inhibitors,research,lifescience,medical chemotherapy-related events. Common surgical complications are bleeding, postoperative bowel obstruction, anastomotic leakage, wound infection, pulmonary embolism and venous thrombosis. Morbidity related with cytostatic agents used in HIPEC is rare but includes leucopenia, Inhibitors,research,lifescience,medical anemia, thrombocytopenia, and liver or renal toxicity. Table 4 Selected series showing morbidity and mortality associated with CRS and HIPEC Figure 3 A. CT scan shows a http://www.selleckchem.com/products/SB-216763.html patient with symptomatic ascites secondary to peritoneal mesothelioma before CRS and HIPEC; B. The patient underwent a successful CRS and HIPEC and remained asymptomatic Inhibitors,research,lifescience,medical and free of imageable disease based on CT scan for over 18 months …
Numerous reports over the past 20 years indicate that mortality and morbidity following cytoreduction with HIPEC is decreasing because of improvements of surgical technique and patient selection criteria (Table 5). Two recent publications addressing mortality and morbidity provide informative data. Glehen and et al. conducted
a retrospective multicenter cohort study in French-speaking Inhibitors,research,lifescience,medical institutions to evaluate toxicity and principal prognostic factors after cytoreduction surgery and HIPEC (14). One thousand two hundred ninety patients from 25 institutions who underwent 1,344 procedures between 1989 and 2007 were included; HIPEC was performed in 1,154 procedures. Inhibitors,research,lifescience,medical Colorectal adenocarcinoma (40.5%), pseudomyxoma peritonei (23.3%), gastric adenocarcinoma (12.3%), peritoneal mesothelioma (6.8%), and appendiceal adenocarcinoma (3.9%) were the principal origins of carcinomatosis. The overall morbidity and mortality rates were 33.6% and 4.1%, respectively. The median survival was 30 months for patients with colorectal cancer, 9 months for patients with gastric cancer, 41 months for patients with peritoneal mesothelioma, and 77 months for patients with cancer from appendiceal adenocarcinoma. Table 5 Summary of features TCL associated with HRQoL questionnaires Gusani et al. reported low mortality in patients treated at a single institution (15). A total of 122 patients underwent 124 cytoreduction and HIPEC procedures. R-0 resection was achieved in 28.7% of cases, R-1 in 54.9%, and R-2 in 16.4%. Median operative time was 460 minutes (range, 250-840 minutes) and median blood loss was 1,150 mL (range, 10-14,000 mL). Grade 3 or 4 morbidity was seen in 29.8% of cases, with overall morbidity 56.5%. Two-year survival was 66.